New trial tests which drug combo works better for young adults with leukemia
NCT ID NCT06917911
Summary
This study aims to find out if adding a newer drug called venetoclax to standard chemotherapy works as well as or better than adding an older targeted drug called gemtuzumab ozogamicin for treating a specific type of acute myeloid leukemia (AML). It will enroll 162 younger adults (ages 18-59) who are newly diagnosed. The main goal is to see which combination leads to a deeper remission with no detectable cancer cells left behind.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.